U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fourth for COVID-19

As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi on Wednesday checks the recombinant protein vaccine box. The product has yet to enter the clinic, but the partners expect approval could come in 1H21.

Additional developments this week include a new lease on life for Kodak, the latest from Akiko Iwasaki’s lab and Reata’s move to repurpose bardoxolone methyl. ...